© 2020 MJH Life Sciences and OncLive. All rights reserved.
July 06, 2020
Nikhil C. Munshi, MD, discusses the next steps for research with idecabtagene vicleucel in relapsed/refractory multiple myeloma.
Nikhil C. Munshi, MD, discusses T-cell persistence with idecabtagene vicleucel demonstrated in the phase 2 KarMMA trial in patients with relapsed /refractory multiple myeloma.
June 30, 2020
Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.
May 29, 2020